Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

938 results about "Specific protein" patented technology

Specific proteins are valuable markers for a variety of diseases including microbial infections, inflammatory response, cardiac risk and even cancer. The complement system is a family of proteins that is integral in the destruction of viruses and bacteria, and is a major part of the immune system.

Identification and comparison of protein-protein interactions that occur in populations and identification of inhibitors of these interactors

InactiveUS6057101AEfficient screeningLess experimentally significant and specific indicationMaterial nanotechnologyFungiDiseaseBinding site
Methods are described for detecting protein-protein interactions, among two populations of proteins, each having a complexity of at least 1,000. For example, proteins are fused either to the DNA-binding domain of a transcriptional activator or to the activation domain of a transcriptional activator. Two yeast strains, of the opposite mating type and carrying one type each of the fusion proteins are mated together. Productive interactions between the two halves due to protein-protein interactions lead to the reconstitution of the transcriptional activator, which in turn leads to the activation of a reporter gene containing a binding site for the DNA-binding domain. This analysis can be carried out for two or more populations of proteins. The differences in the genes encoding the proteins involved in the protein-protein interactions are characterized, thus leading to the identification of specific protein-protein interactions, and the genes encoding the interacting proteins, relevant to a particular tissue, stage or disease. Furthermore, inhibitors that interfere with these protein-protein interactions are identified by their ability to inactivate a reporter gene. The screening for such inhibitors can be in a multiplexed format where a set of inhibitors will be screened against a library of interactors. Further, information-processing methods and systems are described. These methods and systems provide for identification of the genes coding for detected interacting proteins, for assembling a unified database of protein-protein interaction data, and for processing this unified database to obtain protein interaction domain and protein pathway information.
Owner:CURAGEN CORP

Bone matrix compositions and methods

The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and/or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. Ona assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and/or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and/or chondrogenic activity of human DBM when tested using this assay system.
Owner:WARSAW ORTHOPEDIC INC

Whole-blood immunoassay device and blood analyzer with same

ActiveCN103336130AFast implementation of joint inspectionSimplify the cumbersome inspection processColor/spectral properties measurementsBiological testingAbsorbanceControl unit
The invention provides a device and a method for simultaneously carrying out immune measurement and blood cell measurement on whole blood. The device comprises a reaction tank, a hemolytic reagent supplying part, a sample injection part, an immune reagent supplying part, a light irradiation unit, a control unit, a transmission light detection unit, a scattered light detection unit and an analytical calculation unit, wherein the reaction tank is used for reaction and measurement of a hemolytic agent, an immune reagent and a whole blood test sample; the hemolytic reagent supplying part is used for injecting the hemolytic agent into the reaction tank; the sample injection part is used for injecting the whole blood test sample into the reaction tank to form a first test sample; the immune reagent supplying part is used for adding the immune reagent into the first test sample to form a second test sample; the light irradiation unit provides irradiation light; the control unit is used for controlling the temperature of the reaction tank and controlling the hemolytic reagent supplying part, the sample injection part and the immune reagent supplying part to act according to a certain sequence; the transmission light detection unit is used for detecting absorbance of the first test sample; the scattered light detection unit is used for detecting the strength of scattered light of the second test sample; the analytical calculation unit is used for carrying out analytical calculation on the absorbance and the strength of the scattered light to obtain blood routine parameters and specific protein parameters.
Owner:MACCURA MEDICAL INSTR CO LTD

Specific epitope based immunological diagnosis of tuberculosis

The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. Tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria. Four recently characterized proteins with this diagnostic potential were selected. Peptides from these proteins were tested one by one with peripheral blood mononuclear cells from microscopy or culture confirmed TB patients as well as from healthy BCG vaccinated controls. Some combinations of peptides showed a sensitivity level comparable to the level seen with the two wellknown M. tuberculosisspecific proteins ESAT 6 and CFP 10. An epitope combination with these peptides combined with ESAT 6 and CFP 10 gave a sensitivity of 93%, representing a raise in sensitivity of about 26-33% compared to using ESAT6 or CFP 10 alone. The results from a panel of TB patients, using a collection of the new specific epitopes clearly demonstrates, that addition of other specific epitopes to the already known specific antigens, increases the sensitivity of a diagnostic assay based on cell mediated immune response.
Owner:STATENS SERUM INST

Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.
Owner:BRISTOL MYERS SQUIBB CO

Bone tissue repair ink, composition and bracket, and preparation methods thereof as well as kit

The invention relates to the field of bone tissue engineering, in particular to bone tissue repair ink, a bone tissue repair composition and a bone tissue repair bracket, and preparation methods thereof as well as a kit. The bone tissue repair ink and a bioactive carrier wrapping cells are used as raw materials, and the bone tissue repair bracket is printed according to a preset three-dimensionalstructure by adopting a biological printer. Meanwhile, living cell printing is realized by adopting the bone tissue repair ink and the bioactive carrier as the raw materials. The cells are uniformly distributed on a bracket model formed by the bone tissue repair ink and difficultly slide down to the bottom of the bracket, so that the problem that the expression of some characteristic proteins of the cells is easily lost in the prior art is effectively solved. The growth of the cells on the bracket is facilitated. A human body bone cell growth environment is better simulated, the cell proliferation, the directional differentiation and the specific protein expression are promoted, the extension and the migration of the cells in the bone tissue bracket and the cell junction establishment arefacilitated, and an organic construction body is formed.
Owner:REGENOVO BIOTECH

Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer

A protein obtainable from a non pathogenic microorganism, said protein having mucosa binding promoting activity and a molecular weight of 20-40 kD is disclosed. Application of such a protein or a peptide derived therefrom in a method of screening non pathogenic microorganisms for a microorganism capable of specifically binding mucosa, said method comprising detection in a manner known per se of the presence of a particular protein on or in a microorganism or in a culture of microorganisms, said particular protein being the already defined protein. Kits suitable for such a screening method are also disclosed. Use of a component selected from the group of components comprising a protein or peptide as defined an expression vector comprising nucleic acid encoding such protein or peptide a recombinant microorganism or a part of said microorganism expressing such protein or peptide, said part expressing mucosa binding promoting activity a non pathogenic microorganism capable of expressing such protein or peptide or a part of said microorganism, said part expressing mucosa binding promoting activity as pharmaceutically active component in a pharmaceutical composition for prophylaxis and/or treatment of disease or illness associated with a mucosa colonising pathogenic microorganism. Use of such components as food additive and compositions comprising such components are described.
Owner:AGENSYS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products